目的 制定替雷利珠单抗药物利用评价(DUE)标准,为临床合理使用替雷利珠单抗提供参考.方法 以药品说明书为基础,参考指导原则、临床指南和专家共识等资料,建立替雷利珠单抗DUE标准.采用回顾性分析方法,抽取六安市人民医院2021年1月1日至2022年12月31日使用替雷利珠单抗并出院的患者,根据DUE标准进行用药合理性评价.结果 共纳入557例使用替雷利珠单抗的病例,不合理用药主要包括:用药指征不合理15例(占2.69%),用 法用量不合理8例(占1.44%),输注顺序不合理3例(占0.54%),预防性使用激素不合理68例(占12.21%);药品不良反应发生率为26.57%,临床应用有效率为59.96%(334例).结论建立替雷利珠单抗DUE标准可快速提高临床医生对药品信息的掌握水平,促进临床合理用药,减少药品不良反应和患者经济负担.
Objective To establish the drug use evaluation(DUE)criteria of tislelizumab and provide references for the rational use of tislelizumab in clinical practice.Methods The DUE criteria of tislelizumab was established based on the drug instruction and with reference to the guiding principles,clinical guidelines and expert con-sensus,etc.By retrospective analysis,patients who used tislelizumab and were discharged from Lu'an People's Hospital from January 1,2021 to December 31,2022 were selected to evaluate the rationality of drug use according to the DUE criteria.Results A total of 557 medical records of patients using tislelizumab were included,and the irrational drug use was mainly as follows:irrational indication of medication(n=15,2.69%),irrational dosage(n=8,1.44%),irrational infusion order(n=3,0.54%)and irrational prophylactic use of hormones(n=68,12.21%).The incidence of adverse drug reactions was 26.57%;clinical application was effective in 334 cases(59.96%).Conclusion Estab-lishment of DUE criteria for tislelizumab can rapidly improve clinicians'mastery of drug information,promote rational clinical use of drugs,and reduce adverse drug reactions and economic burden.